Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
Clinical trial NCT05396859 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05396859
- Sponsor
- OHSU Knight Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-28
- Primary completion
- 2024-06-10
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.